Next Article in Journal
Machine Learning Approaches for Quality Assessment of Protein Structures
Previous Article in Journal
Structural Insight into the Mechanism of N-Linked Glycosylation by Oligosaccharyltransferase
Open AccessArticle

Association of microRNA Expression and BRAFV600E Mutation with Recurrence of Thyroid Cancer

1
Institute of Biotechnology, Life Sciences Center, Vilnius University, LT- 10257, Sauletekio av. 7, Vilnius, Lithuania
2
Institute of Endocrinology, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Eiveniu str. 2, Kaunas, Lithuania
3
Department of Pathology, Lithuanian University of Health Sciences, LT-50161 Eiveniu str. 2, Kaunas, Lithuania
4
Institute for Digestive Research, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Eiveniu str. 2, Kaunas, Lithuania
*
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(4), 625; https://doi.org/10.3390/biom10040625
Received: 12 February 2020 / Revised: 14 April 2020 / Accepted: 15 April 2020 / Published: 17 April 2020
(This article belongs to the Section Molecular Pathology)
Many miRNAs and cancer-related mutations have been proposed as promising molecular markers of papillary thyroid carcinoma (PTC). However, there are limited data on the correlation between miRNA expression, BRAFV600E mutation, and PTC recurrence. Therefore, to evaluate the potential of BRAFV600E mutation and five selected miRNAs (-146b, -222, -21, -221, -181b) in predicting PTC recurrence, these molecular markers were analyzed in 400 formalin-fixed, paraffin-embedded PTC tissue specimens. The expression levels of miRNAs were measured using qRT-PCR. It was demonstrated that expression levels of all analyzed miRNAs are significantly higher in recurrent PTC than in non-recurrent PTC (p < 0.05). Moreover, higher expression levels of miR-146b, miR-222, miR-21, and miR-221 were associated with other clinicopathologic features of PTC, such as tumor size and lymph node metastases at initial surgery (p < 0.05). No significant differences in the frequency of BRAFV600E mutation in recurrent PTC and non-recurrent PTC were determined. Our results suggest that miRNA expression profile differs in PTC that is prone to recurrence when compared to PTC that does not reoccur after the initial surgery while BRAFV600E mutation frequency does not reflect the PTC recurrence status. However, the prognostic value of the analyzed miRNAs is rather limited in individual cases as the pattern of miRNA expression is highly overlapping between recurrent and non-recurrent PTC. View Full-Text
Keywords: papillary thyroid carcinoma (PTC); miRNA; BRAFV600E mutation; recurrence; biomarkers papillary thyroid carcinoma (PTC); miRNA; BRAFV600E mutation; recurrence; biomarkers
Show Figures

Figure 1

MDPI and ACS Style

Pamedytyte, D.; Simanaviciene, V.; Dauksiene, D.; Leipute, E.; Zvirbliene, A.; Sarauskas, V.; Dauksa, A.; Verkauskiene, R.; Zilaitiene, B. Association of microRNA Expression and BRAFV600E Mutation with Recurrence of Thyroid Cancer. Biomolecules 2020, 10, 625.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop